Feb 28 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) VRX.N VRX.TO on Wednesday reported a profit in the fourth quarter compared to a year-earlier loss, as it booked a one-time benefit because of new U.S. tax laws.
The Canada-based drugmaker reported a net income of $513 million or $1.45 per share in the quarter ended Dec. 31, compared to a loss of $515 million or $1.47 per share a year earlier.
It recorded a one-time benefit from income taxes of $1.32 billion.